|
US5082767A
(en)
|
1989-02-27 |
1992-01-21 |
Hatfield G Wesley |
Codon pair utilization
|
|
IL98528A0
(en)
|
1990-06-21 |
1992-07-15 |
Merck & Co Inc |
Pharmaceutical compositions containing hybrid for killing bladder cancer cells
|
|
US20030148463A1
(en)
|
1997-04-14 |
2003-08-07 |
Micromet Ag |
Novel method for the production of anti-human antigen receptors and uses thereof
|
|
GB9709421D0
(en)
|
1997-05-10 |
1997-07-02 |
Zeneca Ltd |
Chemical compounds
|
|
CA2295189C
(en)
|
1997-06-06 |
2010-11-23 |
Tanox Pharma B.V. |
Type-1 ribosome-inactivating protein
|
|
ATE267215T1
(de)
|
1997-12-08 |
2004-06-15 |
Lexigen Pharm Corp |
Heterodimäre fusionsproteine zur verwendung für gezielte immuntherapie und allgemeine immunerregung
|
|
US6280742B1
(en)
|
1998-06-17 |
2001-08-28 |
Zonagen, Inc. |
Methods and materials for the treatment of prostatic carcinoma
|
|
WO2000061635A2
(en)
|
1999-04-09 |
2000-10-19 |
Universität Zürich |
Method for the stabilization of chimeric immunoglobulins or immunoglobulin fragments, and stabilized anti-egp-2 scfv fragment
|
|
GB9911569D0
(en)
|
1999-05-18 |
1999-07-21 |
Oxford Biomedica Ltd |
Antibodies
|
|
US7829084B2
(en)
|
2001-01-17 |
2010-11-09 |
Trubion Pharmaceuticals, Inc. |
Binding constructs and methods for use thereof
|
|
MXPA03009924A
(es)
|
2001-05-03 |
2004-01-29 |
Merck Patent Gmbh |
Anticuerpo recombinante especifico de tumor y uso del mismo.
|
|
US20030148950A1
(en)
|
2001-10-09 |
2003-08-07 |
Li Xin |
Kringle domain 1 of human hepatocyte growth factor and uses therefor
|
|
JP2005507659A
(ja)
|
2001-10-15 |
2005-03-24 |
イミューノメディクス、インコーポレイテッド |
直接ターゲッティング結合タンパク質
|
|
US20040022726A1
(en)
|
2002-06-03 |
2004-02-05 |
Goldenberg David M. |
Methods and compositions for intravesical therapy of bladder cancer
|
|
SI21272A
(sl)
|
2002-07-31 |
2004-02-29 |
LEK farmacevtska dru�ba d.d. |
Sintetski gen za humani granulocitne kolonije stimulirajoči dejavnik za ekspresijo v E. coli
|
|
CA2424255A1
(en)
|
2003-03-26 |
2004-09-26 |
Claudio Di Paolo |
Immunotoxins
|
|
CA2826735C
(en)
|
2003-04-30 |
2019-06-04 |
University Of Zurich |
Methods for treating cancer using an immunotoxin
|
|
DK1737961T3
(da)
|
2004-03-19 |
2013-08-05 |
Merck Patent Gmbh |
Modificerede bouganin proteiner, cytotoxiner og fremgangsmåder og anvendelser deraf
|
|
NZ552476A
(en)
|
2004-06-10 |
2009-09-25 |
Viventia Biotech Inc |
Tumor specific antibody
|
|
US20090171317A1
(en)
|
2006-03-10 |
2009-07-02 |
Ebrahim Versi |
Self-Catheterization Device To Administes Compounds To The Bladder
|
|
CA2668017A1
(en)
*
|
2006-10-30 |
2008-05-08 |
Viventia Biotech Inc. |
Improved conjugates
|
|
CA2684330A1
(en)
|
2007-04-19 |
2008-10-30 |
Viventia Biotech Inc. |
Optimized nucleotide sequences of vb6-845 for expression of recombinant proteins
|
|
WO2009039630A1
(en)
|
2007-09-27 |
2009-04-02 |
Viventia Biotech Inc. |
Optimized nucleic acid sequences for the expression of vb4-845
|
|
CA2618163A1
(en)
*
|
2008-02-07 |
2009-08-07 |
K. W. Michael Siu |
Head and neck cancer biomarkers
|
|
CA2756246A1
(en)
|
2009-04-08 |
2010-10-14 |
Heinz Faulstich |
Amatoxin-armed target-binding moieties for the treatment of cancer
|
|
GB0909904D0
(en)
|
2009-06-09 |
2009-07-22 |
Affitech As |
Product
|
|
WO2011116387A1
(en)
|
2010-03-19 |
2011-09-22 |
Tetragenetics, Inc. |
Production of aglycosylated monoclonal antibodies in ciliates
|
|
WO2012178173A1
(en)
*
|
2011-06-24 |
2012-12-27 |
Centrose, Llc |
Extracellular targeted drug conjugates
|
|
CA2909153A1
(en)
*
|
2013-04-12 |
2014-10-16 |
Viventia Bio Inc. |
Compositions and methods for detection and treatment of hepatocellular carcinoma
|
|
US20160136211A1
(en)
*
|
2013-06-17 |
2016-05-19 |
Viralytics Limited |
Methods for the treatment of bladder cancer
|
|
DK3052525T3
(da)
|
2013-10-02 |
2019-10-07 |
Viventia Bio Inc |
Anti-epcam-antistoffer og anvendelsesfremgangsmåder
|
|
JP6824183B2
(ja)
|
2015-03-12 |
2021-02-03 |
セセン バイオ，インコーポレイテッド |
Ｅｐｃａｍ陽性膀胱癌の処置方法
|
|
AU2016228760B2
(en)
|
2015-03-12 |
2020-07-16 |
Viventia Bio Inc. |
Dosing strategies for targeting EPCAM positive bladder cancer
|
|
WO2017040801A2
(en)
|
2015-09-02 |
2017-03-09 |
Viventia Bio Inc. |
Methods for making and using an immunoconjugate for the treatment of cancer
|